Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
NCT06365619 · University of Utah · PHASE2 · withdrawn · last registry update 2026-10-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low Accrual” | – | Registry record, University of Utah |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CTLA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-02Also stopped (suspended): National Cancer Institute (NCI), Carboplatin + Ipilimumab (NCT03604991)
- 2026-11-02Also stopped (suspended): National Cancer Institute (NCI), Cabozantinib S-malate + Ipilimumab (NCT05904080)
- 2026-10-27Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Ipilimumab (NCT04317105)
- 2026-10-20Results posted on the registry: Dana-Farber Cancer Institute, Nivolumab + Ipilimumab (NCT04416568)
- 2026-10-20Also stopped (terminated): M.D. Anderson Cancer Center, Ipilimumab + Nivolumab (NCT03274258)
- 2026-10-19Also stopped (suspended): National Cancer Institute (NCI), a drug against CTLA4 (NCT04866810)
- 2026-10-19Phase 3 first posted: Yao Hongwei, Ipilimumab & Sintilimab + Sintilimab (NCT07879599)
- 2026-10-19Phase 3 first posted: Yao Hongwei, Ipilimumab & Sintilimab + Sintilimab (NCT07879586)
- 2026-10-08Also stopped (suspended): City of Hope Medical Center, Ipilimumab + Myrciaria dubia Prebiotic Supplement (NCT06049576)
- 2026-10-01Results posted on the registry: PrECOG, LLC., Durvalumab + Standard Chemotherapy (NCT04334759)
- 2026-09-28Also stopped (terminated): Akeso, AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin (NCT05932212)
- 2026-09-23Also stopped (terminated): Hackensack Meridian Health, Nivolumab + Ipilimumab (NCT05715229)
- 2026-09-11Phase 3 first posted: Fudan University, Second-Line Chemotherapy + Cadonilimab (AK104) (NCT07815834)
- 2026-09-11Phase 3 first posted: Scancell Ltd, iSCIB1+ + Nivolumab & Ipilimumab (NCT07815574)
- 2026-09-04Also stopped (suspended): Washington University School of Medicine, Zanzalintinib + Ipilimumab (NCT06968988)
- 2026-08-20Results posted on the registry: M.D. Anderson Cancer Center, Ipilimumab + Nivolumab (NCT03274258)
- 2026-08-17Also stopped (suspended): National Cancer Institute (NCI), BET Bromodomain Inhibitor ZEN-3694 + Ipilimumab (NCT04840589)
- 2026-08-13Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Quavonlimab (NCT04305041)
- 2026-08-11Results posted on the registry: Agenus Inc., Zalifrelimab + Balstilimab (NCT03495882)
- 2026-08-04Results posted on the registry: Mirati Therapeutics Inc., Sitravatinib + Nivolumab (NCT04887870)
- 2026-08-04Also stopped (terminated): Academic and Community Cancer Research United, Ipilimumab + Nivolumab (NCT05199285)
- 2026-07-22Phase 3 first posted: AstraZeneca, Dato-DXd + Rilvegostomig (NCT07720284)
- 2026-07-16Also stopped (terminated): Dana-Farber Cancer Institute, Ipilimumab + Nivolumab (NCT03425331)
- 2026-07-14Phase 3 first posted: Akeso, Cadonilimab + CAPOX regimen (NCT07700979)
- 2026-07-02Results posted on the registry: Diwakar Davar, Vidutolimod (CMP-001) + Nivolumab (NCT04401995)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision